Literature DB >> 11880404

Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.

M A Pfaller1, D J Diekema, R N Jones, S A Messer, R J Hollis.   

Abstract

From 1 January 1997 through 31 December 2000, 2,047 bloodstream infections (BSIs) due to Candida spp. were reported from hospitals in the United States, Canada, Latin America, and Europe participating in the SENTRY Antifungal Surveillance Program. Among individuals in four age groups (< or =1, 2 to 15, 16 to 64, and > or =65 years) Candida albicans was the most common species, causing 60, 55, 55, and 50% of infections, respectively. C. glabrata caused 17 to 23% of BSIs in those ages 16 to 64 and > or = 65 years, whereas it caused only 3% of BSIs in the individuals in the two younger age groups (P < 0.001). C. parapsilosis (which caused 21 to 24% of BSIs) and C. tropicalis (which caused 7 to 10% of BSIs) were more common than C. glabrata in individuals ages < or =1 year and 2 to 15 years. Isolates of Candida spp. showed a trend of decreasing susceptibility to fluconazole, itraconazole, and amphotericin B with increasing patient age (P < or = 0.01). None of the C. glabrata isolates from individuals < or =1 year old were resistant to fluconazole, whereas they made up 5 to 9% of isolates from individuals ages 16 to 64 and > or =65 years. Isolates of C. tropicalis from patients < or =1 year old were more susceptible to flucytosine (MIC at which 90% of isolates are inhibited [MIC(90)], 0.5 microg/ml; 0% resistant isolates) than those from patients > or =65 years old (MIC(90), 32 microg/ml; 11% resistant isolates). The investigational triazoles posaconazole, ravuconazole, and voriconazole were all highly active against all species of Candida from individuals in all age groups. These data demonstrate differences in the species distributions of pathogens and differences in antifungal resistance among isolates from individuals in the pediatric and adult age groups. Ongoing surveillance will enhance efforts to limit the extent of antifungal resistance in individuals in various age groups.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11880404      PMCID: PMC120278          DOI: 10.1128/JCM.40.3.852-856.2002

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  20 in total

1.  Vertical and horizontal transmission of unique Candida species to premature newborns.

Authors:  L A Waggoner-Fountain; M W Walker; R J Hollis; M A Pfaller; J E Ferguson; R P Wenzel; L G Donowitz
Journal:  Clin Infect Dis       Date:  1996-05       Impact factor: 9.079

2.  Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998.

Authors:  M A Pfaller; R N Jones; G V Doern; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.

Authors:  M A Pfaller; D J Diekema; R N Jones; H S Sader; A C Fluit; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  2001-09       Impact factor: 5.948

4.  International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe).

Authors:  M A Pfaller; R N Jones; G V Doern; A C Fluit; J Verhoef; H S Sader; S A Messer; A Houston; S Coffman; R J Hollis
Journal:  Diagn Microbiol Infect Dis       Date:  1999-09       Impact factor: 2.803

5.  Nosocomial bloodstream infections in United States hospitals: a three-year analysis.

Authors:  M B Edmond; S E Wallace; D K McClish; M A Pfaller; R N Jones; R P Wenzel
Journal:  Clin Infect Dis       Date:  1999-08       Impact factor: 9.079

6.  Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital.

Authors:  Y F Berrouane; L A Herwaldt; M A Pfaller
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

Review 7.  Current and emerging azole antifungal agents.

Authors:  D J Sheehan; C A Hitchcock; C M Sibley
Journal:  Clin Microbiol Rev       Date:  1999-01       Impact factor: 26.132

8.  Management of neonatal candidiasis. Neonatal Candidiasis Study Group.

Authors:  J L Rowen; J M Tate
Journal:  Pediatr Infect Dis J       Date:  1998-11       Impact factor: 2.129

9.  In vitro susceptibilities of Candida bloodstream isolates to the new triazole antifungal agents BMS-207147, Sch 56592, and voriconazole.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones; G V Doern; M E Brandt; R A Hajjeh
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

10.  International surveillance of bloodstream infections due to Candida species: frequency of occurrence and antifungal susceptibilities of isolates collected in 1997 in the United States, Canada, and South America for the SENTRY Program. The SENTRY Participant Group.

Authors:  M A Pfaller; R N Jones; G V Doern; H S Sader; R J Hollis; S A Messer
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

View more
  84 in total

1.  Drug resistance is not directly affected by mating type locus zygosity in Candida albicans.

Authors:  Claude Pujol; Shawn A Messer; Michael Pfaller; David R Soll
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

2.  Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp.

Authors:  A Espinel-Ingroff; M Pfaller; S A Messer; C C Knapp; N Holliday; S B Killian
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

3.  Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility.

Authors:  M A Pfaller; D J Diekema
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

4.  Candida albicans β-Glucan-Containing Particles Increase HO-1 Expression in Oral Keratinocytes via a Reactive Oxygen Species/p38 Mitogen-Activated Protein Kinase/Nrf2 Pathway.

Authors:  Yoko Ishida; Kouji Ohta; Takako Naruse; Hiroki Kato; Akiko Fukui; Hideo Shigeishi; Hiromi Nishi; Kei Tobiume; Masaaki Takechi
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

5.  Candidemia in Norway (1991 to 2003): results from a nationwide study.

Authors:  Per Sandven; Lars Bevanger; Asbjørn Digranes; Hanne H Haukland; Turid Mannsåker; Peter Gaustad
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

6.  Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility.

Authors:  Maiken Cavling Arendrup; Kurt Fuursted; Bente Gahrn-Hansen; Irene Møller Jensen; Jenny Dahl Knudsen; Bettina Lundgren; Henrik C Schønheyder; Michael Tvede
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

7.  Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates.

Authors:  Beth A Arthington-Skaggs; Wendy Lee-Yang; Meral A Ciblak; Joao P Frade; Mary E Brandt; Rana A Hajjeh; Lee H Harrison; Andre N Sofair; David W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location.

Authors:  M A Pfaller; S A Messer; L Boyken; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

Review 9.  Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants.

Authors:  David Kaufman; Karen D Fairchild
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

10.  In vitro activity of voriconazole and other antifungal agents against clinical isolates of Candida glabrata and Candida krusei.

Authors:  M Drago; M M Scaltrito; G Morace
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-16       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.